查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048007

核子醫學治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球核子醫學市場預計將從 2025 年的 9.9812 億美元成長到 2031 年的 17.3474 億美元，複合年成長率高達 9.65%。

該市場主要涉及使用放射性藥物進行精準局部放射治療，以治療特定疾病，尤其是在腫瘤學和心臟病學領域。這些療法透過與細胞表面的生物標記結合發揮作用，有效且精準地清除惡性細胞，同時最大限度地減少對周圍健康組織的損傷。全球人口老化和慢性病的盛行率上升是推動該市場發展的主要動力，也刺激了對高精度治療的需求。預計到2024年，全球將進行5,000萬例核醫檢查，這便是明證。

市場概覽
預測期 2027-2031
市場規模：2025年 9.9812億美元
市場規模：2031年 1,734,740,000 美元
複合年成長率：2026-2031年 9.65%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

儘管前景光明，但全球放射性同位素供應鏈固有的脆弱性是市場擴張的一大障礙。由於治療性同位素的半衰期極短，從生產核子反應爐到臨床應用場所，建立完善快速的物流系統至關重要，任何延誤都是不可接受的。依賴數量有限且往往老舊的生產設施，使得供應極易中斷，進而導致供不應求，最終限制患者獲得這些關鍵且有時效性的治療。

市場促進因素

癌症發生率的激增是全球核醫市場的主要驅動力，也因此增加了對療效優於傳統化療的標靶治療的需求。隨著癌症負擔的加重，醫療系統越來越重視能夠同時診斷和治療腫瘤的放射性藥物。根據國際癌症研究機構（IARC）2024年2月的預測，預計到2050年，新增癌症病例數將從2022年的約2000萬例大幅成長至超過3500萬例。這項預測的激增強烈表明，迫切需要可擴展的治療方案，尤其是在晚期前列腺癌和神經內分泌癌的治療方面，因為精準治療對於最佳療效至關重要。

同時，公共和私人投資的大幅成長（通常表現為策略性收購）正在迅速加速市場成熟並促進創新。領先的製藥公司正積極收購擁有成熟放射性藥物產品組合的生技公司，以鞏固其在這個快速擴張領域的地位。例如，2024年3月，Astra Zeneca宣布達成最終協議，將以約24億美元收購Fusion Pharmaceuticals，將先進的放射性偶聯物整合到其腫瘤產品線中。此類資金注入正在加速產能擴張，並推動新型α射線療法透過各種臨床試驗取得進展。此外，諾華公司公佈的放射性配體療法「Pluvicto」在2024年第三季的銷售額達到3.86億美元，這清楚地表明了這些先進治療方法的商業性可行性及其在臨床實踐中日益成長的應用。

市場挑戰

全球放射性同位素供應鏈固有的脆弱性嚴重阻礙了全球核子醫學治療市場的成長。治療性同位素的物理半衰期極短，因此無法進行庫存儲備，必須採用持續的、即時供應的模式，任何物流錯誤都不可容忍。該市場嚴重依賴數量有限的老舊研究核子反應爐，這意味著即使是計劃外的維護或技術故障也可能立即中斷關鍵治療方法的供應。這種根本性的脆弱性導致市場波動劇烈，即使是輕微的生產中斷也會直接導致即時醫院和診所的供不應求。

這種普遍存在的可靠性不足直接阻礙了市場擴張，因為它經常導致治療中斷，並削弱了臨床醫生對這些關鍵治療方法始終可用的信心。例如，《歐洲核子醫學》雜誌在2024年報告稱，意外的生產延誤導致全球供不應求50%至100%。如此嚴重的供應中斷迫使醫療機構推遲緊急腫瘤和心臟病治療，導致患者容量受限和收入減少。因此，這種普遍存在的不可預測性使得醫療機構不願投資新的核醫基礎設施，最終阻礙了這些精準療法更廣泛的商業性應用。

市場趨勢

一個關鍵的市場趨勢是標靶α療法（TAT）的加速發展。與傳統的BETA射線離子療法相比，TAT利用α粒子卓越的線性能量轉移效率，實現了顯著的進步。與BETA射線不同，α粒子發射的能量集中在一個極窄的範圍內，能夠高效地誘導癌細胞中不可修復的雙鏈DNA斷裂，同時最大限度地減少對周圍健康組織的繼發性損傷。這種更高的治療指數正在推動廣泛的研究和應用，尤其是在治療對標準荷爾蒙療法和BETA射線放射性配體療法產生抗藥性的轉移性癌症方面。為了支持這一研究方向，拜耳公司在2025年5月舉行的ASCO 2025年會上宣布，α射線鐳-223與Enzalutamide的聯合療法顯著改善了治療效果，使轉移性去勢抗性前列腺癌患者的影像學進展或死亡風險降低了31%。

同時，隨著參與企業積極整合其生產和分銷基礎設施以降低物流風險，放射性同位素供應鏈垂直整合的趨勢在市場上日益明顯。透過整合內部生產能力，企業減少了對分散的外部供應商的依賴，並為短半衰期同位素建立了更可靠的「即時」交付系統。這種策略整合加強了對品管、生產計劃和患者獲取的監管，直接解決了長期存在的同位素短缺問題。重大市場交易凸顯了這種一體化物流的重要性。特別是，CapVest Partners在2025年11月對Curium進行約70億美元的重組，明確指出該公司端到端的生產和物流能力是其高估值的關鍵決定因素。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球核子醫學治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（α射線發射裝置、BETA射線發射裝置、近距離放射治療）
    • 依應用領域（腫瘤科、循環系統、甲狀腺科及其他應用領域）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美核子醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲核子醫學治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區核子醫學治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲核子醫學療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲核子醫學治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球核子醫學治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals Inc.
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd
  • NTP Radioisotopes Pty Ltd.
  • Bracco SpA
  • Cardinal Health Inc.
  • Nordion Inc.
  • Triad Isotopes Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18747

The global Nuclear Medicine Therapeutics Market is projected for substantial growth, expanding from USD 998.12 million in 2025 to USD 1734.74 million by 2031, at a robust CAGR of 9.65%. This market leverages radiopharmaceuticals to deliver precise, localized radiation doses for treating specific diseases, primarily in oncology and cardiology. These therapeutic agents operate by attaching to biological markers on cell surfaces, effectively eradicating malignant cells with high precision while minimizing harm to healthy surrounding tissues. The increasing global elderly population combined with a rising incidence of chronic diseases is a significant impetus for the market, fueling the demand for advanced precision treatments, as evidenced by approximately 50 million nuclear medicine procedures performed worldwide in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 998.12 Million
Market Size 2031USD 1734.74 Million
CAGR 2026-20319.65%
Fastest Growing SegmentOncology
Largest MarketNorth America

Despite this positive outlook, a critical hurdle for market expansion is the inherent fragility of the global radioisotope supply chain. The exceptionally short physical half-lives of therapeutic isotopes necessitate an impeccably fast and faultless logistical system from production reactors to clinical delivery, leaving no room for delays. This reliance on a limited number of often outdated production facilities renders the supply vulnerable to disruptions, which can quickly lead to immediate shortages and consequently restrict patient access to these critical, time-sensitive therapies.

Market Driver

The escalating prevalence of cancer serves as the primary impetus for the global nuclear medicine therapeutics market, driving the necessity for targeted treatment modalities that surpass the efficacy of conventional chemotherapy. As the burden of oncological diseases grows, healthcare systems are increasingly emphasizing radiopharmaceuticals capable of both diagnosing and treating tumors concurrently. Projections from the International Agency for Research on Cancer in February 2024 indicate a significant rise in new cancer cases, from an estimated 20 million in 2022 to over 35 million by 2050. This projected surge critically underscores the urgent demand for scalable therapeutic solutions, particularly crucial for managing late-stage prostate and neuroendocrine cancers where treatment precision is paramount for optimal patient outcomes.

Simultaneously, a substantial increase in public and private investment, frequently manifested through strategic acquisitions, is rapidly propelling market maturation and fostering innovation. Leading pharmaceutical companies are actively acquiring biotechnology firms with established radiopharmaceutical portfolios to secure a foothold in this rapidly expanding sector; for instance, AstraZeneca announced in March 2024 its definitive agreement to acquire Fusion Pharmaceuticals for approximately $2.4 billion to integrate advanced radioconjugates into its oncology pipeline. These capital injections are facilitating the expansion of manufacturing capabilities and the progression of novel alpha therapies through various clinical trials, while the reported sales of Novartis' radioligand therapy Pluvicto reaching USD 386 million in the third quarter of 2024 clearly demonstrate the commercial viability and increasing clinical adoption of these sophisticated treatments.

Market Challenge

The inherent fragility of the global radioisotope supply chain presents a significant impediment to the growth of the Global Nuclear Medicine Therapeutics Market. Given the extremely short physical half-lives of therapeutic isotopes, stockpiling is not feasible, necessitating a continuous, just-in-time delivery model that offers absolutely no tolerance for logistical errors. The market's heavy dependence on a limited number of aging research reactors means that any unscheduled maintenance or technical malfunctions can instantaneously disrupt the availability of critical treatments. This fundamental vulnerability introduces substantial market volatility, wherein even minor production halts translate directly into immediate downstream shortages for hospitals and clinics.

This pervasive unreliability directly obstructs market expansion by frequently leading to procedure cancellations and eroding clinician confidence in the consistent availability of these vital therapies. For example, Nuclear Medicine Europe reported in 2024 that unexpected production delays resulted in supply shortfalls ranging from 50% to 100% across various global regions. Such severe interruptions compel healthcare providers to defer urgent oncological and cardiac interventions, thereby limiting patient throughput and diminishing revenue generation. Consequently, this pervasive unpredictability dissuades institutions from investing in new nuclear medicine infrastructure, ultimately hindering the broader commercial adoption of these precision treatments.

Market Trends

A significant market trend is the accelerating development of Targeted Alpha Therapy (TAT), marking a crucial evolution beyond traditional beta-emitters by harnessing the superior linear energy transfer of alpha particles. Unlike beta radiation, alpha particles deliver concentrated energy payloads over an extremely confined range, efficiently inducing irreparable double-strand DNA breaks in tumor cells while simultaneously minimizing collateral damage to surrounding healthy tissues. This enhanced therapeutic index is stimulating extensive clinical research and adoption, particularly for managing metastatic cancers that have become refractory to standard hormonal or beta-emitting radioligand therapies. Supporting this approach, Bayer's May 2025 announcement at ASCO 2025 indicated that integrating the alpha-emitter radium-223 with enzalutamide substantially improved outcomes, reducing the risk of radiological progression or death by 31% in patients with metastatic castration-resistant prostate cancer.

Concurrently, the market is exhibiting a distinct trend towards the verticalization of radioisotope supply chains, as industry participants proactively consolidate manufacturing and distribution infrastructure to alleviate logistical vulnerabilities. By integrating production capabilities internally, companies are reducing their dependence on fragmented external suppliers, thereby establishing a more reliable "just-in-time" delivery system for short-lived isotopes. This strategic consolidation grants greater oversight concerning quality control, scheduling, and ensuring patient access, directly confronting the persistent challenge of isotope scarcity. The importance of such integrated logistics is underscored by major market transactions, notably CapVest Partners' November 2025 recapitalization of Curium at approximately $7 billion, explicitly attributing its end-to-end manufacturing and logistics capabilities as a primary determinant of its high valuation.

Key Market Players

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals Inc.
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd
  • NTP Radioisotopes Pty Ltd.
  • Bracco SpA
  • Cardinal Health Inc.
  • Nordion Inc.
  • Triad Isotopes Inc.

Report Scope

In this report, the Global Nuclear Medicine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nuclear Medicine Therapeutics Market, By Type

  • Alpha Emitters
  • Beta Emitters
  • Brachytherapy

Nuclear Medicine Therapeutics Market, By Application

  • Oncology
  • Cardiology
  • Thyroid
  • Other Applications

Nuclear Medicine Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine Therapeutics Market.

Available Customizations:

Global Nuclear Medicine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nuclear Medicine Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Alpha Emitters, Beta Emitters, Brachytherapy)
    • 5.2.2. By Application (Oncology, Cardiology, Thyroid, Other Applications)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Nuclear Medicine Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nuclear Medicine Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Nuclear Medicine Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Nuclear Medicine Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Nuclear Medicine Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nuclear Medicine Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Nuclear Medicine Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Nuclear Medicine Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Nuclear Medicine Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Nuclear Medicine Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Nuclear Medicine Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nuclear Medicine Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Nuclear Medicine Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Nuclear Medicine Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Nuclear Medicine Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Nuclear Medicine Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Nuclear Medicine Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nuclear Medicine Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Nuclear Medicine Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Nuclear Medicine Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Nuclear Medicine Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nuclear Medicine Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Nuclear Medicine Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Nuclear Medicine Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nuclear Medicine Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Actinium Pharmaceutical Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Alpha Tau Medical Ltd
  • 15.3. Bayer AG
  • 15.4. Fusion Pharmaceuticals Inc.
  • 15.5. IBA Radiopharma Solutions
  • 15.6. RadioMedix Inc.
  • 15.7. Telix Pharmaceuticals Ltd
  • 15.8. NTP Radioisotopes Pty Ltd.
  • 15.9. Bracco SpA
  • 15.10. Cardinal Health Inc.
  • 15.11. Nordion Inc.
  • 15.12. Triad Isotopes Inc.

16. Strategic Recommendations

17. About Us & Disclaimer